We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.29%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.31B
AUM Growth
+$931M
Cap. Flow
+$3.42M
Cap. Flow %
0.05%
Top 10 Hldgs %
41.19%
Holding
233
New
22
Increased
88
Reduced
44
Closed
17

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$66M
2
CRL icon
Charles River Laboratories
CRL
+$38M
3
WVE icon
Wave Life Sciences
WVE
+$20.8M
4
ABT icon
Abbott
ABT
+$19M
5
PACB icon
Pacific Biosciences
PACB
+$17.1M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$108M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$84.7M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$53.2M
4
GILD icon
Gilead Sciences
GILD
+$35.4M
5
TDOC icon
Teladoc Health
TDOC
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Industrials 0.45%
3 Technology 0.42%
4 Communication Services 0.09%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
226
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-116,000
Closed -$593K
ALXN
227
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-150
Closed -$113K
PTLA
228
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-43,700
Closed -$1.17M
STML
229
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-31,500
Closed -$328K
AGN
230
DELISTED
Allergan plc
AGN
– –
-30,800
Closed -$5.18M
MDCO
231
DELISTED
Medicines Co
MDCO
– –
-28,900
Closed -$1.45M
ALDR
232
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-4,492,466
Closed -$84.7M
CELG
233
DELISTED
Celgene Corp
CELG
– –
-1,085,600
Closed -$108M
6 7 8 9
10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2019 Portfolio in Review

As of Q4 2019, Bellevue Group held 233 positions worth $6.31B, up 17% from $5.38B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q4 2019 filing shows 22 new, 88 increased, 44 reduced and 17 closed positions. Its largest new stake was Molecular Templates, Inc.: 86,379 shares worth $18.1M. The largest sale was Celgene Corp, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q4 2019 buy was Molecular Templates, Inc.: 86,379 shares worth $18.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $66M increase.
  • Bellevue Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $53.2M.
  • Bellevue Group fully exited Celgene Corp in Q4 2019, selling an estimated $108M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.31B portfolio in Q4 2019.
  • Bellevue Group opened 22 new positions and closed 17 in Q4 2019.
  • Bellevue Group's portfolio value rose 17% quarter-over-quarter to $6.31B.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.